A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer

被引：0

作者：

Itani, Yoshio ^{[1
]}

Hosokawa, Kenichi ^{[2
]}

Ito, Kimihiko ^{[3
]}

Takeuchi, Satoshi ^{[4
]}

Tabata, Tsutomu ^{[5
]}

Tsubamoto, Hiroshi ^{[6
]}

Fujita, Hiroyuki ^{[7
]}

Akiyama, Minoru ^{[8
]}

Adachi, Susumu ^{[6
,9
]}

机构：

[1] Nara Prefectural Nara Hosp, Nara, Japan

[2] Kyoto Prefectural Univ Med, Kyoto, Japan

[3] Kansai Rosai Hosp, Hyogo, Japan

[4] Kobe Natl Hosp, Kobe, Hyogo, Japan

[5] Mie Univ, Tsu, Mie, Japan

[6] Hyogo Coll Med, Nishinomiya, Hyogo, Japan

[7] Kyoto Second Red Cross Hosp, Kyoto, Japan

[8] Shiga Med Univ, Shiga, Japan

[9] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA

来源：

ANTICANCER RESEARCH | 2009年 / 29卷 / 05期

关键词：

Epithelial ovarian cancer; treatment resistant; phase I/II study; gemcitabine; docetaxel; PEGYLATED LIPOSOMAL DOXORUBICIN; PLATINUM-BASED CHEMOTHERAPY; II TRIAL; FALLOPIAN-TUBE; PACLITAXEL; CARCINOMA; RECURRENT; MALIGNANCIES; CARBOPLATIN; PERITONEUM;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: A phase I/II study of docetaxel (DOC) and gemcitabine (GEM) combination for treatment-resistant ovarian cancer (OC) was conducted. Materials and Methods: Eligible patients exhibited recurrent OC within 12 months after initial treatment, or after more than 2 chemotherapy regimens. Planned dose levels (DL) were as follows: DOC 70 mg/m(2), GEM 800 mg/m(2) (DL1); DOC 70 mg/m(2), GEM 1000 mg/m(2) (DL2). DOC was administered on day 1 combined with GEM on days 1 and 8 every 3 weeks. Adverse events were assessed by NCI-CTC2.0J. Response was evaluated by RECIST or Rustin's criteria. Results: The recommended dose was DL1. For all enrolled patients, the median interval from last chemotherapy was 2.5 (1-11) months and 32 patients were assessable for response. One complete response, 6 partial responses and 6 stable disease were noted. Median time to progression was 4.8 months. Toxicities were mainly hematological and Manageable. Conclusion: This combination could be an acceptable treatment option before palliation.

引用

页码：1521 / 1526

页数：6

共 34 条

[1] Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer [J].